Jeffrey has made over 16 trades of the Artivion Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 36,273 units of CRY stock worth $674,315 on 14 March 2018.
The largest trade he's ever made was exercising 133,188 units of Artivion Inc stock on 10 February 2017 worth over $1,406,465. On average, Jeffrey trades about 11,956 units every 20 days since 2016. As of 14 March 2018 he still owns at least 809,685 units of Artivion Inc stock.
You can see the complete history of Mr. Burbank stock trades at the bottom of the page.
Jeffrey H. Burbank is Independent Director of the Company. Mr. Burbank has served as a director of CryoLife since October 2017. Mr. Burbank is the Chief Technology Officer at Fresenius Medical Care North America, a division of Fresenius Medical Care (NYSE: FMS), the world’s largest provider of products and services for individuals with renal diseases. Prior to that, Mr. Burbank served as Chief Executive Officer and a member of the board of directors of NxStage Medical, Inc. (formerly NASDAQ: NXTM) (“NxStage Medical”), a leading medical technology company, positions he held since he founded NxStage Medical in 1998, until Fresenius Medical Care completed its acquisition of NxStage Medical in February 2019. Prior to founding NxStage Medical, Mr. Burbank was a co-founder of Vasca, Inc., a company that provided innovative implantable access devices, where he was the President and Chief Executive Officer, as well as Chairman of the Board. Mr. Burbank has over 30 years of senior leadership experience in the medical device industry, developing, marketing, and manufacturing products for end-stage renal disease patients. During his career he has been an inventor on over 50 U.S. patents for medical devices. Mr. Burbank received a B.S. in Industrial Engineering from Lehigh University.
As the Independent Director of Artivion Inc, the total compensation of Jeffrey Burbank at Artivion Inc is $175,015. There are 16 executives at Artivion Inc getting paid more, with James Mackin having the highest compensation of $6,453,540.
Jeffrey Burbank is 57, he's been the Independent Director of Artivion Inc since 2017. There are 8 older and 15 younger executives at Artivion Inc. The oldest executive at Artivion Inc is Ronald McCall, 83, who is the Presiding Independent Director.
Jeffrey's mailing address filed with the SEC is 1655, Roberts Boulevard Northwest, Kennesaw, Cobb County, Georgia, 30144, United States of America.
Over the last 21 years, insiders at Artivion Inc have traded over $18,346,910 worth of Artivion Inc stock and bought 91,700 units worth $1,086,548 . The most active insiders traders include Steven G Anderson, Thomas F Ackerman et James P Mackin. On average, Artivion Inc executives and independent directors trade stock every 26 days with the average trade being worth of $211,842. The most recent stock trade was executed by Amy Horton on 8 December 2021, trading 2,500 units of CRY stock currently worth $46,425.
Headquartered in suburban Atlanta, Georgia, CryoLife is a leader in the manufacturing, processing, and distribution of medical devices and implantable tissues used in cardiac and vascular surgical procedures focused on aortic repair. CryoLife markets and sells products in more than 100 countries worldwide.
Artivion Inc executives and other stock owners filed with the SEC include: